Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Type
3.2. Market Snippet by Drug Class
3.3. Market Snippet by Distribution Channel
3.4. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. The latest treatment for Gastroesophageal Reflux Disease is expected to drive market growth.
4.1.2. Restraints:
4.1.2.1. Side effects associated with the drugs is expected to hamper the market growth.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Supply Chain Analysis
5.2. Pricing Analysis
5.3. Unmet Needs
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type Segment
7.2. Mild*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Moderate
7.4. Severe
8. By Drug Class
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
8.1.2. Market Attractiveness Index, By Drug Class Segment
8.2. Antacids*
8.2.1. Aluminum hydroxide gel (Alternagel, Amphojel)
8.2.2. Calcium carbonate (Alka-Seltzer, Tums)
8.2.3. Magnesium hydroxide (Milk of Magnesia)
8.2.4. Pepto-Bismol
8.2.5. Others
8.2.6. Introduction
8.2.7. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Proton Pump Inhibitors
8.3.1. Esomeprazole (Nexium)
8.3.2. Lansoprazole (Prevacid)
8.3.3. Omeprazole (Prilosec, Zegerid)
8.3.4. Pantoprazole (Protonix)
8.3.5. Rabeprazole (Aciphex)
8.3.6. Dexlansoprazole (Dexilant)
8.3.7. Others
8.4. Histamine blockers
8.4.1. Cimetidine (Tagamet HB)
8.4.2. Famotidine (Pepcid AC)
8.4.3. Nizatidine
8.4.4. Others
8.5. Pro-Kinetic Agents
8.6. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel Segment
9.2. Hospital Pharmacy*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Retail Pharmacy
9.4. Online Pharmacy
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
11.4. List of Key Companies to Watch
12. Company Profiles
12.1. Merck Sharp & Dohme Pty Ltd.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. McNeil Consumer Pharmaceuticals Co.
12.3. Amneal Pharmaceuticals LLC
12.4. AstraZeneca Pharmaceuticals LP
12.5. Teva Pharmaceuticals USA, Inc.
12.6. Takeda Pharmaceuticals America, Inc.
12.7. Eisai R&D Management Co., Ltd
12.8. TWi Pharmaceuticals USA, Inc.
12.9. Lannett
12.10. Saol Therapeutics Inc(*LIST NOT EXHAUSTIVE)
13. DataM Intelligence
13.1. Appendix
13.2. About Us and Applications
13.3. Contact Us